Other compounds

RAD-140: molecular data, studies & sources

RAD-140 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-09 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF): C20H16ClN5O2
Molecular weight (MW): 393.8 g/mol
PubChem compound ID: 44200882
Record title: 2-Chloro-4-(((1R,2S)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropyl)amino)-3-methylbenzonitrile

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 44200882 · retrieved 2026-10-09

2D molecular structure for RAD-140, PubChem CID 44200882 — 2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.

Chemical identifiers and source data

IUPAC name: 2-chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile
InChIKey: XMBUPPIEVAFYHO-KPZWWZAWSA-N
SMILES: CC1=C(C=CC(=C1Cl)C#N)N[C@@H](C2=NN=C(O2)C3=CC=C(C=C3)C#N)[C@H](C)O

Machine-readable PubChem source

Identifiers

PubChem CID: 44200882
CAS Registry Number: 1182367-47-0via ChemIDplus, EPA DSSTox, FDA GSRS
FDA UNII: 4O87Q44KNC
ChEMBL ID: CHEMBL1672635
InChIKey: XMBUPPIEVAFYHO-KPZWWZAWSA-N
Wikidata: Q25099854

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-09.

Calculated molecular descriptors

Monoisotopic (exact) mass	393.0993 Da
Heavy atoms	28
Hydrogen-bond donors	2
Hydrogen-bond acceptors	7
Rotatable bonds	5
Topological polar surface area	118.8 Å²
Calculated logP (Crippen)	3.98
Rings	3
Stereocenters	2
Formal charge	0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Drug development record (ChEMBL)

Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.

ChEMBL ID: CHEMBL1672635
Modality: Small molecule
Highest clinical stage: Phase 2
Record name: RAD-140

Synonyms, codes and trade names

Synonyms and development codes: RAD140 · Vosilasarm

Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL1672635 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-09

Registered clinical trials

Studies registered on ClinicalTrials.gov that list RAD-140 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

1 registered study matched.

By highest phase: Phase 1 · 1
By registry status: Completed · 1

Study	Phase · status	Conditions	Sponsor · size
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast CancerNCT03088527 · start 2017-10-23 · primary completion 2020-08-28	Phase 1Completed	Hormone Receptor Positive Malignant Neoplasm of Breast	Stemline Therapeutics, Inc.20 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received RAD-140, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Case report
Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033).
Barbara M, Dhingra S, Mindikoglu AL et al. · ACG case reports journal · 2020
PMID 33062783 · DOI: 10.14309/crj.0000000000000409
Case report
Myopericarditis Following Use of Selective Androgen Receptor Modifier "RAD-140".
Schwartzman KH, Kohli U, Chaudhuri NR et al. · JACC. Case reports · 2024
PMID 39157568 · DOI: 10.1016/j.jaccas.2024.102423
Preclinical / laboratory research
Label-free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses.
Cheung HW, Wong KS, To NS et al. · Drug testing and analysis · 2021
PMID 33277807 · DOI: 10.1002/dta.2988
Research publication · design requires review
Unregulated gains: a case of RAD-140-induced liver injury.
Dao D, King B, Dao H et al. · Proceedings (Baylor University. Medical Center) · 2026
PMID 42417499 · DOI: 10.1080/08998280.2026.2691619
Research publication · design requires review
Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes.
Wagener F, Euler L, Görgens C et al. · Metabolites · 2022
PMID 35888790 · DOI: 10.3390/metabo12070666
Preclinical / laboratory research
Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats.
Jayaraman A, Christensen A, Moser VA et al. · Endocrinology · 2014
PMID 24428527 · DOI: 10.1210/en.2013-1725
Case report
Selective androgen receptor modulator abuse-induced heart failure: catastrophic effects of RAD-140 (Testolone).
Skorupski WJ, Marko A, Janus M et al. · Polish archives of internal medicine · 2024
PMID 38864168 · DOI: 10.20452/pamw.16770
Case report
Acute Myocarditis From the Use of Selective Androgen Receptor Modulator (SARM) RAD-140 (Testolone).
Padappayil RP, Chandini Arjun A, Vivar Acosta J et al. · Cureus · 2022
PMID 35233331 · DOI: 10.7759/cureus.21663

RAD-140 supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

PubChem compound record 44200882 — chemical identity and structure.
ChEMBL drug record CHEMBL1672635 — development stage, mechanism and synonyms.
FDA Global Substance Registration System: UNII 4O87Q44KNC — substance identity, names and codes.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.